Abstract Number: 0210 • ACR Convergence 2023
Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors
Background/Purpose: T cells are critical for control of viral infection with SARS-CoV-2, but knowledge is lacking on cellular immune responses following repeated vaccination and breakthrough…Abstract Number: 0932 • ACR Convergence 2023
The Landscape of Immune Cells in Systematic Lupus Erythematosus Patients with Epstein-Barr Virus Infection by Single-cell Sequencing
Background/Purpose: This study aimed to analyze the immune cell profiles, especially B cells and B-cell receptor (BCR) of systematic lupus erythematosus (SLE) patients with or…Abstract Number: 1553 • ACR Convergence 2023
Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis
Background/Purpose: Central nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). On the other hand, AAV patients may develop complications or other conditions…Abstract Number: 2116 • ACR Convergence 2023
Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of tuberculosis, particularly in association with the use of biologic disease-modifying anti-rheumatic…Abstract Number: 2566 • ACR Convergence 2023
Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database
Background/Purpose: Targeted therapies have demonstrated their efficacy in the treatment of psoriatic arthritis (PsA), with an increased risk of serious infections. However, a comparison of…Abstract Number: 0211 • ACR Convergence 2023
COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated vaccine responses and are prone to severe infections. Knowledge of COVID-19 outcome following…Abstract Number: 0970 • ACR Convergence 2023
Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change
Background/Purpose: British Columbia's health policy mandated that all new anti-TNF initiations after June 2017 use biosimilars when available, providing the context for a natural experiment.…Abstract Number: 1584 • ACR Convergence 2023
Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study
Background/Purpose: Infections during treatment of ANCA-associated vasculitis (AAV) lead to excess mortality. Trimethoprim sulfamethoxazole (TMP-SMX), recommended for pneumocystis jirovecii pneumonia (PJP) prophylaxis, has broad antimicrobial…Abstract Number: 2120 • ACR Convergence 2023
Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections
Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated…Abstract Number: 0215 • ACR Convergence 2023
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…Abstract Number: 0981 • ACR Convergence 2023
Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors
Background/Purpose: Infections are a known complication of disease-modifying therapy in rheumatic patients but have also been associated with the diseases being treated. Biosimilars have increased…Abstract Number: 1619 • ACR Convergence 2023
Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis
Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…Abstract Number: 2267 • ACR Convergence 2023
Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 1.85-fold higher risk of all-cause mortality and a 2.74 fold higher risk of infection-related mortality compared…Abstract Number: 0218 • ACR Convergence 2023
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…Abstract Number: 0983 • ACR Convergence 2023
Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study
Background/Purpose: Dengue is the leading vectorborne disease globally with half of the global population at risk, including Puerto Rico in the United States. Previously, we…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 32
- Next Page »